TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non–small-cell lung cancer
RS Herbst, D Prager, R Hermann… - Journal of clinical …, 2005 - ascopubs.org
… with chemotherapy were conducted. No antagonism was detected with any of the chemotherapy
agents evaluated, including paclitaxel and … of erlotinib, including paclitaxel and cisplatin. …
agents evaluated, including paclitaxel and … of erlotinib, including paclitaxel and cisplatin. …
TRIBUTE-A phase III trial of erlotinib HCl (OSI-774) combined with carboplatin and paclitaxel (CP) chemotherapy in advanced non-small cell lung cancer (NSCLC)
RS Herbst, D Prager, R Hermann, V Miller… - Journal of Clinical …, 2004 - ascopubs.org
… Conclusions: Erlotinib combined with carboplatin and paclitaxel chemotherapy did not confer
a survival advantage over carboplatin and paclitaxel alone in pts with previously untreated …
a survival advantage over carboplatin and paclitaxel alone in pts with previously untreated …
Erlotinib Hydrochloride
LA Sorbera, J Castaner, JS Silvestre… - Drugs of the Future, 2002 - access.portico.org
… of erlotinib in combination with other chemotherapeutic … mg erlotinib + paclitaxel/carboplatin
and a DLT of grade 3 rash was seen in 2 patients administered 150 mg erlotinib + paclitaxel/…
and a DLT of grade 3 rash was seen in 2 patients administered 150 mg erlotinib + paclitaxel/…
Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines
Q Dai, YH Ling, M Lia, YY Zou, G Kroog, KK Iwata… - Clinical Cancer …, 2005 - AACR
… Results: Enhanced sensitivity to erlotinib was observed in the doxorubicin-resistant human
breast cancer cell line MCF-7, paclitaxel-resistant human ovarian carcinoma cell line A2780, …
breast cancer cell line MCF-7, paclitaxel-resistant human ovarian carcinoma cell line A2780, …
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors
A Patnaik, D Wood, AW Tolcher, M Hamilton… - Clinical cancer …, 2006 - AACR
… No survival benefit or improvement in response rate versus chemotherapy … of erlotinib and
paclitaxel were, however, apparent in this study. Patients received 200 mg/m 2 of paclitaxel …
paclitaxel were, however, apparent in this study. Patients received 200 mg/m 2 of paclitaxel …
Chemotherapy plus erlotinib versus chemotherapy alone for treating advanced non-small cell lung cancer: a meta-analysis
JL Xu, B Jin, ZH Ren, YQ Lou, ZR Zhou, QZ Yang… - PloS one, 2015 - journals.plos.org
… erlotinib plus paclitaxel based chemotherapy versus paclitaxel based chemotherapy alone
[16]… In this meta-analysis, continuous erlotinib plus chemotherapy versus chemotherapy alone …
[16]… In this meta-analysis, continuous erlotinib plus chemotherapy versus chemotherapy alone …
FDA Drug Approval Summary: Erlotinib (Tarceva®) Tablets
MH Cohen, JR Johnson, YF Chen, R Sridhara… - The …, 2005 - academic.oup.com
… chemotherapy will be randomized to receive either erlotinib … based chemotherapy will be
randomized to receive erlotinib, … Inc.) chemotherapy. The primary end point is overall survival. …
randomized to receive erlotinib, … Inc.) chemotherapy. The primary end point is overall survival. …
Erlotinib (Tarceva): an update on the clinical trial program
RS Herbst - Seminars in oncology, 2003 - Elsevier
… erlotinib was similar to that with various chemotherapeutic … -fluorouracil 31 and 7.3 months
with paclitaxel plus cisplatin). … using erlotinib in combination with docetaxel, paclitaxel plus …
with paclitaxel plus cisplatin). … using erlotinib in combination with docetaxel, paclitaxel plus …
Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non–small-cell lung cancer
… In another randomized phase II study, a 7-day EGFR TKI–free period was scheduled before
each subsequent cycle of carboplatin/paclitaxel chemotherapy in patients with chemotherapy…
each subsequent cycle of carboplatin/paclitaxel chemotherapy in patients with chemotherapy…
Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial
… to chemotherapy plus erlotinib (n=226) or chemotherapy … with chemotherapy plus erlotinib
versus chemotherapy plus … in the chemotherapy plus erlotinib and chemotherapy plus placebo …
versus chemotherapy plus … in the chemotherapy plus erlotinib and chemotherapy plus placebo …
相关搜索
- cell lung cancer erlotinib hcl
- intercalated combination of chemotherapy and erlotinib
- receptor tyrosine kinase inhibitor erlotinib hydrochloride
- phase iii trial paclitaxel chemotherapy
- erlotinib for treatment prior chemotherapy regimen
- standard chemotherapy in patients agent erlotinib
- erlotinib in combination paclitaxel and carboplatin
- conventional chemotherapy efficacy of erlotinib
- standard chemotherapy trial of erlotinib
- carboplatin and paclitaxel erlotinib hcl
- fastact 2 chemotherapy and erlotinib
- sub-group analysis erlotinib hcl
- long survival erlotinib hcl
- tumor cell lines erlotinib hydrochloride
- phase iii trial erlotinib hcl
- enhanced sensitivity erlotinib hydrochloride